DOP2020000119A - Conjugados anticuerpo anti-cd40-fármaco - Google Patents

Conjugados anticuerpo anti-cd40-fármaco

Info

Publication number
DOP2020000119A
DOP2020000119A DO2020000119A DO2020000119A DOP2020000119A DO P2020000119 A DOP2020000119 A DO P2020000119A DO 2020000119 A DO2020000119 A DO 2020000119A DO 2020000119 A DO2020000119 A DO 2020000119A DO P2020000119 A DOP2020000119 A DO P2020000119A
Authority
DO
Dominican Republic
Prior art keywords
antibody conjugates
drug antibody
antibody
formula
drug conjugates
Prior art date
Application number
DO2020000119A
Other languages
English (en)
Inventor
Wang Lu
H Bryant Shaughn
D Hobson Adrian
C Marvin Christopher
Waegell Wendy
Z Oh Jason
Hernandez Axel Jr
C Santora Ling
L Mcpherson Michael
L Ihle Claire
A Perntg Olivia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2020000119A publication Critical patent/DOP2020000119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan conjugados anticuerpo anti-CD40-fármaco que comprenden un radical de la Fórmula (I), en donde R1, R2 y R3 son como se definen en la presente. Además se proporcionan conjugados anticuerpo anti-CD40-fármaco de la Fórmula (II), en donde Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2 y R3 son como se definen en la presente. Además se proporcionan composiciones farmacéuticas y kits de estas, y métodos para usarlos.
DO2020000119A 2017-12-01 2020-06-15 Conjugados anticuerpo anti-cd40-fármaco DOP2020000119A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US201762595045P 2017-12-05 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
DOP2020000119A true DOP2020000119A (es) 2020-08-31

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000119A DOP2020000119A (es) 2017-12-01 2020-06-15 Conjugados anticuerpo anti-cd40-fármaco

Country Status (19)

Country Link
US (1) US20220265842A1 (es)
EP (1) EP3716982A4 (es)
JP (1) JP2021504430A (es)
KR (1) KR20200095493A (es)
CN (1) CN111465399A (es)
AU (1) AU2018374633A1 (es)
BR (1) BR112020010691A2 (es)
CA (1) CA3081559A1 (es)
CL (1) CL2020001442A1 (es)
CR (1) CR20200285A (es)
DO (1) DOP2020000119A (es)
EC (1) ECSP20034868A (es)
IL (1) IL274650A (es)
MX (1) MX2020005465A (es)
PE (1) PE20201464A1 (es)
PH (1) PH12020550551A1 (es)
RU (1) RU2020117156A (es)
SG (1) SG11202004865SA (es)
WO (1) WO2019106608A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3125886A1 (en) * 2019-01-11 2020-07-16 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
WO2022166779A1 (zh) * 2021-02-04 2022-08-11 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
TW202304462A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
EP4365183A1 (en) * 2021-06-24 2024-05-08 Jiangsu Simcere Pharmaceutical Co., Ltd. Steroid compound, and pharmaceutical composition thereof and use thereof
EP4393937A1 (en) * 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
CN118201943A (zh) * 2021-09-14 2024-06-14 映恩生物制药（苏州）有限公司 一种抗炎症的化合物及其用途
WO2023245106A1 (en) * 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途
WO2024140903A1 (zh) * 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2225256T3 (da) * 2007-11-30 2013-03-11 Pfizer Ltd Nye glucocorticoidreceptoragonister
JP2011507878A (ja) * 2007-12-21 2011-03-10 シェーリング コーポレイション Ｃ２０−ｃ２１置換グルココルチコイド受容体アゴニスト
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
DK3303395T3 (da) * 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
IL274650A (en) 2020-06-30
PH12020550551A1 (en) 2021-03-22
US20220265842A1 (en) 2022-08-25
ECSP20034868A (es) 2020-08-31
RU2020117156A (ru) 2022-01-04
PE20201464A1 (es) 2020-12-17
KR20200095493A (ko) 2020-08-10
JP2021504430A (ja) 2021-02-15
MX2020005465A (es) 2020-09-07
WO2019106608A1 (en) 2019-06-06
CA3081559A1 (en) 2019-06-06
CL2020001442A1 (es) 2020-09-11
EP3716982A4 (en) 2021-08-11
BR112020010691A2 (pt) 2020-11-10
CN111465399A (zh) 2020-07-28
EP3716982A1 (en) 2020-10-07
CR20200285A (es) 2020-09-04
SG11202004865SA (en) 2020-06-29
AU2018374633A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
UY38140A (es) Picolinamidas como fungicidas
EA201791550A1 (ru) Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
CO2017004782A2 (es) Conjugados de anticuerpo- farmaco
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
BR112021011124A2 (pt) Anelossomos e métodos de uso
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
CO2019013718A2 (es) Anticuerpos anti-trkb
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
BR112023024837A2 (pt) Anticorpos anti-ccr8
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner